^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Colorectal Cancer
    Drug:Tyvyt (sintilimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

    Excerpt:
    ...Cohort 1: Biopsy tissues with IHC indicates deficient mismatch repair(dMMR),that is,the loss of at least one of the four proteins ,MSH1,MSH2,MSH6,PMS2;or gene detection implies MSI-H; Cohort 2: Biopsy tissues with IHC indicates proficient mismatch repair(pMMR),that is positivity of all four proteins ,MSH1,MSH2,MSH6,PMS2;or gene detection implies MSS/MSI-L 3....
    Trial ID:
    B2019-149
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

    Excerpt:
    ...Locally confirmed defective mismatch repair (dMMR) tumour (as defined by the lack of staining on either the pre-operative biopsy samples or resection specimens of at least one of the following proteins: MLH1 (mutL homolog 1), MSH2 (mutS homologue 2), MSH6 (mutS homolog 6), PMS2 6....
    Trial ID:
    NCT05236972
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

    Excerpt:
    ...With DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) status, whether or...
    Trial ID:
    NCT04636008
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    The safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in MSI-H/dMMR rectal cancer: a prospective, single-arm, multicenter, phase Ib study

    Excerpt:
    ...The patients diagnosed as dMMR by immunohistochemistry or MSI-H (PCR or NGS) by gene detection whatever it's Lynch syndrome or not; 3. ...
    Trial ID:
    ChiCTR2000037604
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Colorectal Cancer
    Title:

    Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer

    Published date:
    11/25/2022
    Excerpt:
    All patients received 6 sintilimab...After 6 injections of neoadjuvant anti-PD-1 therapy, 90.9% (10/11) of the patients (those confirmed to have dMMR and MSI-H disease) achieved pathological complete response (pCR)….Single-agent neoadjuvant PD-1 antibody immunotherapy was safe and effective in locally advanced dMMR/MSI-H CRC.
    DOI:
    10.1016/j.clcc.2022.11.004
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Single-agent neoadjuvant immunotherapy of PD-1 antibody in resectable mismatch repair-deficient/microsatellite instability-high colorectal cancer.

    Published date:
    05/26/2022
    Excerpt:
    ...eight resectable dMMR/MSI-H CRC patients treated in the 6th Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) were enrolled. All patients accepted 6 doses (200mg/dose, every 3 weeks) of Sintilimab injection (Innovent, LTD) before radical laparoscopic resections....After 6 doses of neoadjuvant anti-PD-1 therapy, 87.5% (7/8) of the patients achieved pathological complete response (pCR), and the 7 patients were confirmed both dMMR and MSI-H.
    DOI:
    10.1200/JCO.2022.40.16_suppl.e15605